Stock Analysis

SPYRE THERAPEUTICS INC COM NEW (SYRE)

Loading... + Investors. Track Smart Money conviction in SYRE. See who's accumulating, reducing, or initiating positions.

Loading...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +13
Streak
2Q ▲
Buyers last Q
70%

Smart Money Signals — SYRE

Based on 127 hedge funds · latest filing: 2025 Q4 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds added this stock than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term trade.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
127 hedge funds hold this stock right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a 'crowded trade' — high ownership doesn't mean safe.
📶

Steady growth — +19% more funds vs a year ago

fund count last 6Q
+20 new funds entered over the past year (+19% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟢

More buyers than sellers — 70% buying

87 buying38 selling
Last quarter: 87 funds were net buyers (26 opened a brand new position + 61 added to an existing one). Only 38 were sellers (25 trimmed + 13 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+8 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 20 → 15 → 18 → 26. A growing number of new institutional buyers means the stock is still being discovered — the opportunity hasn't been fully priced in.
📌

Mixed — 27% long-term, 25% new

27% conviction (2yr+) 48% medium 25% new
Of the 127 current holders: 34 (27%) held >2 years, 61 held 1–2 years, and 32 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💰

Value +144% but shares only +26% — price-driven

Value
+143%
Shares
+26%
Last quarter: the total dollar value of institutional holdings rose +144%, but actual share count only changed +26%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📈

Growing discovery — still being found

24 → 20 → 15 → 18 → 26 new funds/Q
New funds entering each quarter: 20 → 15 → 18 → 26. A growing number of institutions are discovering this stock each quarter. The idea is still spreading — there is room for more buyers to enter.
📊

Mixed cohorts — 21% veterans, 37% new entrants

21% veterans 42% 1-2yr 37% new
Of 130 current holders: 27 (21%) held 2+ years, 55 held 1–2 years, 48 (37%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

Strong quality — 21% from major AUM funds

21% from top-100 AUM funds
27 of 127 current holders rank in the top 100 by AUM. A meaningful share of the ownership base comes from the most well-resourced institutions.
3.9
out of 10
Low Exit Risk
Exit risk score 3.9/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Hedge Fund Ownership: SYRE

How many hedge funds hold SYRE — quarterly history vs. share price
Quarterly hedge fund ownership of SYRE vs. share price

Market Analysis: SYRE

View More

Analyst Price Targets

-- Low
-- High
-- Average
-- Current

Analyst Recommendations

Stock Performance

Real-time

Company Profile: SYRE

-- --
Hedge Fund Positioning: SYRE
Loading... + Investors

Track Smart Money conviction in SYRE. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2025 Q4) Prior (2025 Q3) Change

Statistics: SYRE

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --
Institutional Holders (2025 Q4)
Loading... + investors

Track Smart Money conviction in SYRE. See who's accumulating, reducing, or initiating positions.

Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy
Price
13F Score™ 3Y / 7Y Shares Mkt Value Change Change % Source Quarter Filed